See how NEXLETOL and NEXLIZET work

The only ACL inhibitor: a targeted mechanism of action that works upstream from, and is complementary to, statins1-4


Target of inhibition

NEXLETOL is not activated in skeletal muscle1,3

NEXLETOL is primarily activated in the liver1,3


ACL=adenosine triphosphate citrate lyase; LDL-C=low-density lipoprotein cholesterol; ACSVL1=very long-chain acyl-coenzyme A synthetase-1; HMGR=3-hydroxy-3-methyl-glutaryl-coenzyme A reductase.

References: 1. NEXLETOL. Prescribing information. ESPERION Therapeutics, Inc.; 2020. 2. Saeed A, Ballantyne CM. Bempedoic acid (ETC-1002): a current review. Cardiol Clin. 2018;36(2):257-264. 3. Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7(13457):1-13. 4. Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134-151. 5. NEXLIZET. Prescribing information. ESPERION Therapeutics, Inc.; 2020. 6. ZETIA. Prescribing information. Merck & Co., Inc.; 2013.